Clopidogrel Bisulfate
Product Images NDC 62034-017

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 62034-017). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Blenheim Pharmacal, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

300mg 3x10ud 30ct (62034 017 73)

CLOPIDOGREL TABLETS, USP 300mg in 30 (3x10) are unit-dose, non-child resistant tablets that should be kept away from children. The medication guide provided should be given to the patient by the pharmacist. The package insert should be consulted for dosage instructions. Store at 25°C (77°F), with permissible excursions to 15° to 30°C (59° to 86°F) according to USP Controlled Room Temperature. The tablets contain 391.5 mg of clopidogrel bisulfate, USP equivalent to 300 mg of clopidogrel base. The drug product is from NDC 50228-121, ScieGen Pharmaceuticals, Inc. Marketed by Blenheim Pharmacal, Inc. Revision date is November 2015.*

FDA Label Image

Figure 1 (Clopidogrel Fig1)

This appears to be a chart or table providing information on the effect of co-administered PPL on the active metabolite AUC of various drugs at different doses. The drugs evaluated are likely dexlansoprazole, lansoprazole, pantoprazole, and omeprazole. However, the content is not interpretable without additional context or formatting, so any further interpretation or description may not be accurate.*

FDA Label Image

Figure 2 (Clopidogrel Fig2)

The given text represents a table showing the cumulative event rate (%) for cardiovascular death, myocardial infarction, and stroke over a period of months of follow-up for two drug treatments: placebo (+aspirin) and clopidogrel bisulfate (+ aspirin). The text further notes that other standard therapies were used as appropriate.*

FDA Label Image

Figure 3 (Clopidogrel Fig3)

This is a medical report detailing various statistics related to Percent Events, including the number of events and various treatments used. The data is divided by age group, race, and previous medication and includes a breakdown of the number of individuals in each category. There is also a notation that other standard therapies were used as appropriate.*

FDA Label Image

Figure 4 (Clopidogrel Fig4)

This appears to be a statistical report comparing the placebo group with the group taking Clopidogrel. The report includes the number of deaths and a percentage of risk reduction associated with taking Clopidogrel. The data is presented over a period of up to 25 days since randomization.*

FDA Label Image

Figure 5 (Clopidogrel Fig5)

FDA Label Image

Figure 6 (Clopidogrel Fig6)

FDA Label Image

Figure 7 (Clopidogrel Fig7)

FDA Label Image

Figure 8 (Clopidogrel Fig8)

FDA Label Image

Structure (Clopidogrel Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.